This company listing is no longer active
Dingdang Health Technology Group Toekomstige groei
Future criteriumcontroles 1/6
Dingdang Health Technology Group is forecast to grow earnings and revenue by 94.7% and 13.1% per annum respectively. EPS is expected to grow by 115.1% per annum. Return on equity is forecast to be -0.2% in 3 years.
Belangrijke informatie
94.7%
Groei van de winst
115.1%
Groei van de winst per aandeel
| Consumer Retailing winstgroei | 29.1% |
| Inkomstengroei | 13.1% |
| Toekomstig rendement op eigen vermogen | -0.2% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 04 Jun 2024 |
Recente toekomstige groei-updates
Recent updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 6,850 | 31 | 98 | 174 | 1 |
| 12/31/2025 | 6,040 | -37 | 22 | 101 | 2 |
| 12/31/2024 | 5,412 | -120 | -113 | 9 | 2 |
| 6/30/2024 | 4,877 | -198 | -156 | -140 | N/A |
| 3/31/2024 | 4,867 | -212 | -89 | -73 | N/A |
| 12/31/2023 | 4,857 | -226 | -21 | -5 | N/A |
| 9/30/2023 | 4,722 | -1,297 | -44 | -28 | N/A |
| 6/30/2023 | 4,587 | -2,368 | -67 | -50 | N/A |
| 3/31/2023 | 4,465 | -2,491 | -169 | -146 | N/A |
| 12/31/2022 | 4,329 | -2,833 | -264 | -238 | N/A |
| 9/30/2022 | 4,177 | -1,951 | -259 | -233 | N/A |
| 6/30/2022 | 4,025 | -1,069 | -255 | -228 | N/A |
| 3/31/2022 | 3,886 | -1,232 | -290 | -266 | N/A |
| 12/31/2021 | 3,679 | -1,578 | -320 | -295 | N/A |
| 12/31/2020 | 2,229 | -924 | -215 | -193 | N/A |
| 12/31/2019 | 1,276 | -277 | -292 | -266 | N/A |
| 12/31/2018 | 585 | -108 | -1 | 10 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 9886 is forecast to remain unprofitable over the next 3 years.
Winst versus markt: 9886 is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: 9886 is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: 9886's revenue (13.1% per year) is forecast to grow faster than the Hong Kong market (7.3% per year).
Hoge groei-inkomsten: 9886's revenue (13.1% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: 9886 is forecast to be unprofitable in 3 years.